Pure Global

POWDER FOR CONCENTRATE TO BE USED IN THE PREPARATION OF KANGINTI 150 MG SOLUTION FOR INFUSION, 1 PIECE - Turkey License 7ab6dd80a1a1abcce6d6e72707d7babd

Access comprehensive regulatory information for POWDER FOR CONCENTRATE TO BE USED IN THE PREPARATION OF KANGINTI 150 MG SOLUTION FOR INFUSION, 1 PIECE in Turkey's pharmaceutical market through Pure Global AI's free database. This pharmaceutical product is licensed under Turkey number 7ab6dd80a1a1abcce6d6e72707d7babd with license number 2020/270and contains active ingredient trastuzumab. The license is held by AMGEN İLAÇ TİC. LTD. ŞTİ..

This page provides complete pharmaceutical specifications, regulatory compliance details. Pure Global AI offers free access to 21,000+ Turkish pharmaceutical product licenses, helping global pharma companies navigate Turkey SFDA regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
21,000+ Products
7ab6dd80a1a1abcce6d6e72707d7babd
License Details
Turkey SFDA License: 7ab6dd80a1a1abcce6d6e72707d7babd
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Product Details

POWDER FOR CONCENTRATE TO BE USED IN THE PREPARATION OF KANGINTI 150 MG SOLUTION FOR INFUSION, 1 PIECE
TR: KANJİNTİ 150 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 1 ADET
Pharmaceutical Product

License Details

7ab6dd80a1a1abcce6d6e72707d7babd

2020/270

8699862270038

L01FD01

License Holder Information

Active Ingredient

trastuzumab

License Information

Dec 22, 2020